Cardiac Amyloidosis

2
Pipeline Programs
4
Companies
6
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Life Molecular Imaging
Life Molecular ImagingGermany - Berlin
2 programs
1
1
[18F]florbetabenPhase 31 trial
Florbetaben F18Phase 11 trial
Active Trials
NCT06790394RecruitingEst. Sep 2026
NCT05184088RecruitingEst. Mar 2026
Pfizer
PfizerNEW YORK, NY
3 programs
Cardiac amyloidosis deep learning modelN/A
International Cardiac Amyloidosis RegistryN/A1 trial
diagnostic algorithmN/A1 trial
Active Trials
NCT06894290Recruiting300Est. Jul 2026
NCT04459169Unknown424Est. Dec 2021
BridgeBio Pharma
BridgeBio PharmaCA - Palo Alto
1 program
Cardiac amyloidosis deep learning modelN/A1 trial
Active Trials
NCT06469372Completed50Est. Aug 2025
Providence Therapeutics
1 program
EchoNet-LVH AssessmentN/A1 trial
Active Trials
NCT06664866Enrolling By InvitationEst. Nov 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Life Molecular Imaging[18F]florbetaben
Life Molecular ImagingFlorbetaben F18
Providence TherapeuticsEchoNet-LVH Assessment
BridgeBio PharmaCardiac amyloidosis deep learning model
PfizerInternational Cardiac Amyloidosis Registry
Pfizerdiagnostic algorithm

Clinical Trials (6)

Total enrollment: 774 patients across 6 trials

NCT05184088Life Molecular Imaging[18F]florbetaben

Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

Start: Jan 2023Est. completion: Mar 2026
Phase 3Recruiting
NCT06790394Life Molecular ImagingFlorbetaben F18

Test-retest Study With [18F]FBB in Cardiac Amyloidosis

Start: Oct 2025Est. completion: Sep 2026
Phase 1Recruiting
NCT06664866Providence TherapeuticsEchoNet-LVH Assessment

AI Echocardiographic Screening of Cardiac Amyloidosis

Start: Oct 2024Est. completion: Nov 2026
N/AEnrolling By Invitation
NCT06469372BridgeBio PharmaCardiac amyloidosis deep learning model

Cardiac Amyloidosis Discovery Trial

Start: May 2024Est. completion: Aug 202550 patients
N/ACompleted
NCT06894290PfizerInternational Cardiac Amyloidosis Registry

International Cardiac Amyloidosis Registry

Start: Jun 2023Est. completion: Jul 2026300 patients
N/ARecruiting
NCT04459169Pfizerdiagnostic algorithm

Cardiac Amyloidosis : Diagnostic Using Red Flag Signals

Start: Sep 2020Est. completion: Dec 2021424 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 774 patients
4 companies competing in this space